Treatment of hypertension in patients with type-2 diabetes mellitus

Sverre E. Kjeldsen, Ingrid Os, C. Farsang, Jean Michel Mallion, Lennart Hansson, Peter Sleight

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The consensus for treatment of hypertension in type 2 diabetes is now aggressive blood pressure lowering treatment (<130/85 mmHg), usually with polypharmacy. Although treatment with ACE inhibitors has been shown effective in preventing macro- and microvascular events in high risk diabetics with controlled hypertension, we are awaiting the results of ongoing randomized hypertension trials with large subpopulations of type-2 diabetics such as ALLHAT [11], ASCOT [12], CONVINCE [13], INSIGHT [14], LIFE [15], VALUE [16] and nephropathy studies (ABCD-2 V, CSGTEI, IDNT, RENAAL) to clarify the preferred drug(s) of choice for the treatment of hypertension in these patients. Altogether these trials have randomized > 30 000 hypertensive patients with type-2 diabetes. They are being monitored closely; ALLHAT has the largest subset of type-2 diabetics (n > 15 000) and there has not been any need of early termination [17] except that the alpha-blocker arm was stopped [18].

Original languageEnglish
Pages (from-to)1345-1346
Number of pages2
JournalJournal of Hypertension
Volume18
Issue number9
Publication statusPublished - 2000

Fingerprint

Type 2 Diabetes Mellitus
Hypertension
Blood Pressure
Therapeutics

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology

Cite this

Kjeldsen, S. E., Os, I., Farsang, C., Mallion, J. M., Hansson, L., & Sleight, P. (2000). Treatment of hypertension in patients with type-2 diabetes mellitus. Journal of Hypertension, 18(9), 1345-1346.

Treatment of hypertension in patients with type-2 diabetes mellitus. / Kjeldsen, Sverre E.; Os, Ingrid; Farsang, C.; Mallion, Jean Michel; Hansson, Lennart; Sleight, Peter.

In: Journal of Hypertension, Vol. 18, No. 9, 2000, p. 1345-1346.

Research output: Contribution to journalArticle

Kjeldsen, SE, Os, I, Farsang, C, Mallion, JM, Hansson, L & Sleight, P 2000, 'Treatment of hypertension in patients with type-2 diabetes mellitus', Journal of Hypertension, vol. 18, no. 9, pp. 1345-1346.
Kjeldsen SE, Os I, Farsang C, Mallion JM, Hansson L, Sleight P. Treatment of hypertension in patients with type-2 diabetes mellitus. Journal of Hypertension. 2000;18(9):1345-1346.
Kjeldsen, Sverre E. ; Os, Ingrid ; Farsang, C. ; Mallion, Jean Michel ; Hansson, Lennart ; Sleight, Peter. / Treatment of hypertension in patients with type-2 diabetes mellitus. In: Journal of Hypertension. 2000 ; Vol. 18, No. 9. pp. 1345-1346.
@article{b31af96db1044aa586534e40952ece20,
title = "Treatment of hypertension in patients with type-2 diabetes mellitus",
abstract = "The consensus for treatment of hypertension in type 2 diabetes is now aggressive blood pressure lowering treatment (<130/85 mmHg), usually with polypharmacy. Although treatment with ACE inhibitors has been shown effective in preventing macro- and microvascular events in high risk diabetics with controlled hypertension, we are awaiting the results of ongoing randomized hypertension trials with large subpopulations of type-2 diabetics such as ALLHAT [11], ASCOT [12], CONVINCE [13], INSIGHT [14], LIFE [15], VALUE [16] and nephropathy studies (ABCD-2 V, CSGTEI, IDNT, RENAAL) to clarify the preferred drug(s) of choice for the treatment of hypertension in these patients. Altogether these trials have randomized > 30 000 hypertensive patients with type-2 diabetes. They are being monitored closely; ALLHAT has the largest subset of type-2 diabetics (n > 15 000) and there has not been any need of early termination [17] except that the alpha-blocker arm was stopped [18].",
author = "Kjeldsen, {Sverre E.} and Ingrid Os and C. Farsang and Mallion, {Jean Michel} and Lennart Hansson and Peter Sleight",
year = "2000",
language = "English",
volume = "18",
pages = "1345--1346",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Treatment of hypertension in patients with type-2 diabetes mellitus

AU - Kjeldsen, Sverre E.

AU - Os, Ingrid

AU - Farsang, C.

AU - Mallion, Jean Michel

AU - Hansson, Lennart

AU - Sleight, Peter

PY - 2000

Y1 - 2000

N2 - The consensus for treatment of hypertension in type 2 diabetes is now aggressive blood pressure lowering treatment (<130/85 mmHg), usually with polypharmacy. Although treatment with ACE inhibitors has been shown effective in preventing macro- and microvascular events in high risk diabetics with controlled hypertension, we are awaiting the results of ongoing randomized hypertension trials with large subpopulations of type-2 diabetics such as ALLHAT [11], ASCOT [12], CONVINCE [13], INSIGHT [14], LIFE [15], VALUE [16] and nephropathy studies (ABCD-2 V, CSGTEI, IDNT, RENAAL) to clarify the preferred drug(s) of choice for the treatment of hypertension in these patients. Altogether these trials have randomized > 30 000 hypertensive patients with type-2 diabetes. They are being monitored closely; ALLHAT has the largest subset of type-2 diabetics (n > 15 000) and there has not been any need of early termination [17] except that the alpha-blocker arm was stopped [18].

AB - The consensus for treatment of hypertension in type 2 diabetes is now aggressive blood pressure lowering treatment (<130/85 mmHg), usually with polypharmacy. Although treatment with ACE inhibitors has been shown effective in preventing macro- and microvascular events in high risk diabetics with controlled hypertension, we are awaiting the results of ongoing randomized hypertension trials with large subpopulations of type-2 diabetics such as ALLHAT [11], ASCOT [12], CONVINCE [13], INSIGHT [14], LIFE [15], VALUE [16] and nephropathy studies (ABCD-2 V, CSGTEI, IDNT, RENAAL) to clarify the preferred drug(s) of choice for the treatment of hypertension in these patients. Altogether these trials have randomized > 30 000 hypertensive patients with type-2 diabetes. They are being monitored closely; ALLHAT has the largest subset of type-2 diabetics (n > 15 000) and there has not been any need of early termination [17] except that the alpha-blocker arm was stopped [18].

UR - http://www.scopus.com/inward/record.url?scp=0033816811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033816811&partnerID=8YFLogxK

M3 - Article

C2 - 10994767

AN - SCOPUS:0033816811

VL - 18

SP - 1345

EP - 1346

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - 9

ER -